Waddell & Reed Financial’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
$43M Buy
334,904
+71,636
+27% +$8.83M 0.09% 273
2020
Q4
$31.4M Buy
263,268
+30,291
+13% +$3.69M 0.07% 313
2020
Q3
$26.7M Buy
232,977
+22,260
+11% +$2.63M 0.06% 297
2020
Q2
$24M Buy
210,717
+17,826
+9% +$1.89M 0.06% 296
2020
Q1
$15.5M Sell
192,891
-24,701
-11% -$2.56M 0.05% 315
2019
Q4
$23.2M Buy
217,592
+14,980
+7% +$1.56M 0.06% 325
2019
Q3
$21.7M Hold
202,612
– – 0.06% 321
2019
Q2
$20.6M Sell
202,612
-14,632
-7% -$1.41M 0.05% 340
2019
Q1
$19.5M Buy
217,244
+57,985
+36% +$5.02M 0.05% 346
2018
Q4
$13.3M Buy
159,259
+51,535
+48% +$4.83M 0.04% 373
2018
Q3
$11.6M Buy
107,724
+17,654
+20% +$1.94M 0.03% 391
2018
Q2
$9.9M Sell
90,070
-4,370
-5% -$455K 0.02% 419
2018
Q1
$9.47M Sell
94,440
-2,990
-3% -$306K 0.02% 422
2017
Q4
$9.6M Buy
97,430
+33,940
+53% +$3.22M 0.02% 429
2017
Q3
$5.95M Buy
+63,490
New +$6.74M 0.01% 458

Other funds holding DGX

Waddell & Reed Financial's DGX Position: Q1 2021 in Review

Waddell & Reed Financial increased its Quest Diagnostics (DGX) stake by 27% in Q1 2021, buying an estimated $8.83M and bringing the position to 334,904 shares worth $43M. The position accounts for 0.09% of the portfolio, ranked #273.

Waddell & Reed Financial first reported a position in DGX in Q3 2017 and has held it in 15 quarters since. 817 funds tracked by Wall St. Rank hold DGX as of Q1 2021.

  • Waddell & Reed Financial held 334,904 shares of Quest Diagnostics worth $43M as of Q1 2021.
  • Waddell & Reed Financial bought 71,636 Quest Diagnostics shares in Q1 2021, an estimated $8.83M.
  • Quest Diagnostics made up 0.09% of Waddell & Reed Financial's portfolio in Q1 2021, its #273 holding.
  • Waddell & Reed Financial first reported a position in Quest Diagnostics in Q3 2017 and has held it in 15 quarters since.
  • 817 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.